• Finalised preclinical data for DEP® HER2-Lu and completed GMP dendrimer manufacture.
• Filed new patent application for DEP® technology in radioligand therapy.
• Achieved a milestone under Radiopharm Theranostics collaboration, triggering a $0.5M option fee.
• High engagement at BIO International Convention focused on Star Navigator and DEP® opportunities.
• Cash balance of $11.0 million at 30 June 2026.

Starpharma Holdings Ltd, an innovative biotechnology company, released its Quarterly Activities Report for the quarter ended 30 June 2026. Key highlights include the completion of the preclinical data package for DEP® HER2-Lu, a proprietary radiopharmaceutical, and the commencement of GMP dendrimer manufacture, supporting the planned first-in-human Phase 1 clinical study in H2 CY2026. The company also filed a new patent application in July 2026, covering DEP® technology in radioligand therapy. Starpharma achieved a key milestone under its collaboration with Radiopharm Theranostics, triggering a $0.5 million option fee and commencing the option period for an exclusive license. The company participated in the BIO International Convention, generating positive feedback on its DEP® HER2-Lu program. Starpharma ended FY26 with a cash balance of $11.0 million, reflecting a 149% increase in customer receipts compared to FY25.